On Thursday, in the course of current trade, Shares of Monsanto Company (NYSE:MON), climbed 0.88%, and is now trading at $97.95.
Monsanto Company, declared that its Board of Directors declared a quarterly dividend on its common stock of 54 cents per share. The dividend relates to the company’s fourth quarter of its 2015 fiscal year and is payable on October 30, 2015, to shareowners of record on October 9, 2015.
“The enhance in our quarterly dividend underscores Monsanto’s continued commitment of returning value to our shareowners,” said Pierre Courduroux, senior vice president and chief financial officer for Monsanto. “Monsanto has raised its dividend six times since the end of fiscal year 2010, more than doubling over that time period.”
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces row crop seeds, counting corn, soybean, cotton, and canola seeds principally under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds compriseing of tomato, pepper, melon, cucumber, pumpkin, squash, beans, broccoli, onions, lettuce, and other seeds under the Seminis and De Ruiter brands.
During an Afternoon trade, Shares of Imperva Inc (NYSE:IMPV), raised 4.28%, and is now trading at $60.77.
Imperva, committed to protecting business-critical data and applications in the cloud and on-premises, declared recently that Karl Soderlund has been designated as the company’s Vice President of Worldwide Channels and Alliances. In his role at Imperva, Soderlund will be responsible for transforming the channel and alliance program by both expanding relationships with existing managed service providers and value-added resellers and distributors, in addition to by adding new classes of partners to support the company’s growth. He will report directly to Chief Revenue Officer, Michael D. Mooney.
“We are thrilled to have Karl lead our channel strategy at Imperva. His strong technology sales and channel background, and history of growing revenue and energizing channel programs, makes him the perfect fit for our company and our growth precedingities,” said Michael D. Mooney, Chief Revenue Officer of Imperva. “Expanding the channel is a precedingity as we respond to the steady drum beat of data breaches in the industry. Working with a select group of world-class partners to deliver the Imperva platform and related services, we continue to assist enterprises discover their assets and risks, protect their business critical apps and data and comply with regulations.”
Imperva, Inc. develops, markets, sells, services, and supports cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. It operates in two segments, Imperva and Incapsula.
Finally, Immunomedics, Inc. (NASDAQ:IMMU), gained 2.12% Thursday.
Immunomedics, declared the appointment of Arthur S. Kirsch, 63, to its Board of Directors. Mr. Kirsch has over 30 years of experience working in the equity capital markets and has extensive knowledge of the healthcare and life sciences field. He is Chairman of the Board of Pozen Inc. since June 1, 2015, serving as a Director since 2004; he also has been Chairman of the Audit Committee and Head of the Planned Transaction Committee of Pozen.
Since 2005, Mr. Kirsch has been a Senior Advisor with the investment bank, GCA Savvian, LLC (formerly Perseus Group, LLC). Preceding to GCA Savvian, he was a Managing Director of Vector Securities, LLC, an investment and merchant banking firm specializing in bioscience, which later became a unit of Prudential Securities, Inc. Preceding to Vector, he was Chief Executive Officer of NatWest Securities U.S. From 1979 to 1990, Mr. Kirsch served as Executive Vice President of the Global Equity Division of Drexel Burnham Lambert. He also serves on the Board of Directors of PhysioSonics, Inc., a privately-held company developing noninvasive neurological products.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
